ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access authorization from the U.S. Food and Drug Administration, FDA, for its Cancer BioShield platform, anchored by ANKTIVA, to treat lymphopenia, a life-threatening immune deficiency induced by radiotherapy, chemotherapy, and immunotherapy.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

The Expanded Access covers all patients with solid tumors who failed first-line treatment on radiotherapy, immunotherapy, or chemotherapy, and exhibit low Absolute Lymphocyte Counts (ALC <1,000/μL).

On June 4, H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on ImmunityBio Inc. (NASDAQ:IBRX) and set a price target of $8.00, highlighting the company’s innovative approach to the treatment of lymphopenia.

He supported the optimistic outlook with ImmunityBio Inc.’s (NASDAQ:IBRX) Cancer BioShield platform, including ANKTIVA and PD-L1 t-haNK CAR-NK cells, citing that it attained notable regulatory milestones, such as an Expanded Access authorization from the FDA and RMAT designation. These milestones reflect the potential of the company’s therapies in complicated cancer cases.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.